Overview
My research interests focus on the study of chronic liver disease and primary liver cancer, particularly from metabolic dysfunction associated steatotic liver disease (MASLD), formerly called nonalcoholic fatty liver disease (NAFLD). As part of the MASLD Research Team at Duke, we are investigating the role of environmental contaminants, epigenetics, and genetics on the development of advanced fibrosis and liver cancer from MASLD and other chronic liver diseases. We are also interested in understanding risks for progressive liver disease including developmental programming and in utero exposures and have been investigating these risks through studies of the Newborn Epigenetics Study (NEST). The long term goal of our research is to develop non-invasive biomarkers to identify those patients at increased risk for cirrhosis and end stage liver disease in order to risk stratify patients as well as to develop better preventative and therapeutic strategies.
Current Appointments & Affiliations
Professor of Medicine
·
2025 - Present
Medicine, Gastroenterology,
Medicine
Associate Professor in Pathology
·
2018 - Present
Pathology,
Clinical Science Departments
Member of the Duke Cancer Institute
·
2014 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
Renin-angiotensin-aldosterone system inhibitor use improves clinical outcomes in patients with metabolic dysfunction-associated steatotic liver diseases: Target trial emulation using real-world data.
Journal Article Hepatology · February 1, 2026 BACKGROUND AND AIMS: Angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) prevent fibrosis progression in a preclinical model of steatotic liver disease. Our objective was to assess the impact of ACEi/ARB use on clinical ... Full text Link to item CitePractice changing RCT design and rationale: Abbreviated MRI plus AFP vs. ultrasound plus AFP for HCC surveillance in cirrhosis (PREMIUM study).
Journal Article JHEP Rep · February 2026 Abdominal ultrasound every 6 months with or without serum alpha-fetoprotein (AFP) is recommended for hepatocellular carcinoma (HCC) screening in patients with cirrhosis. However, high-quality evidence demonstrating that this screening strategy reduces HCC- ... Full text Link to item CiteLessons learned from viral hepatitis testing that inform law and policy responses to steatotic liver disease.
Journal Article Nat Rev Gastroenterol Hepatol · January 30, 2026 Liver diseases account for 1 in 25 deaths worldwide. Owing to the asymptomatic nature across the dynamic spectrum of steatotic liver disease (SLD) and the absence of targeted screening programmes, individuals at risk of progression to cirrhosis or hepatoce ... Full text Link to item CiteRecent Grants
Genomic Imprinting in the Development of NAFLD
ResearchPrincipal Investigator · Awarded by National Institute of Diabetes and Digestive and Kidney Diseases · 2024 - 2028Therapeutic modulation of a proteomic HCC risk signature with statins in patients with liver cirrhosis
ResearchCo-Principal Investigator · Awarded by University of Texas - Southwestern · 2023 - 2027The Southeastern Liver Health Cohort Study
ResearchPrincipal Investigator · Awarded by North Carolina State University · 2023 - 2027View All Grants
Education, Training & Certifications
University of Miami ·
2002
M.D.